High dose of human plasma-derived FVIII-VWF as first-line therapy in patients affected by acquired haemophilia A and concomitant cardiovascular disease: four case reports and a literature review.
E
E
Zanon
M
M
Milan
B
B
Brandolin
S
S
Barbar
L
L
Spiezia
G
G
Saggiorato
P
P
Simioni
F
F
Baudo
D000368:Aged; D002318:Cardiovascular Diseases; D005169:Factor VIII / Q000008:administration & dosage*; D006467:Hemophilia A / Q000188:drug therapy*; D006470:Hemorrhage / Q000517:prevention & control; D006490:Hemostatics / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage; D014841:von Willebrand Factor / Q000008:administration & dosage*
D006490:Hemostatics; D011994:Recombinant Proteins; D014841:von Willebrand Factor; D005169:Factor VIII